Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,011 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized Evaluation of a Remote Management Program to Improve Guideline-directed Medical Therapy: The Diabetes Remote Intervention to Improve Use of Evidence-based Medications (DRIVE) Trial.
Blood AJ, Chang LS, Hassan S, Chasse J, Stern G, Gabovitch D, Zelle D, Colling C, Aronson SJ, Figueroa C, Collins E, Ruggiero R, Zacherle E, Noone J, Robar C, Plutzky J, Gaziano TA, Cannon CP, Wexler DJ, Scirica BM. Blood AJ, et al. Among authors: cannon cp. Circulation. 2024 Apr 7. doi: 10.1161/CIRCULATIONAHA.124.069494. Online ahead of print. Circulation. 2024. PMID: 38583146
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.
Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk; Cholesterol Treatment Trialists’ (CTT) Collaboration. Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk, et al. Lancet Diabetes Endocrinol. 2024 May;12(5):306-319. doi: 10.1016/S2213-8587(24)00040-8. Epub 2024 Mar 27. Lancet Diabetes Endocrinol. 2024. PMID: 38554713
Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease.
Berman AN, Biery DW, Besser SA, Singh A, Shiyovich A, Weber BN, Huck DM, Divakaran S, Hainer J, Kaur G, Blaha MJ, Cannon CP, Plutzky J, Januzzi JL, Booth JN 3rd, López JAG, Kent ST, Nasir K, Di Carli MF, Bhatt DL, Blankstein R. Berman AN, et al. Among authors: cannon cp. J Am Coll Cardiol. 2024 Mar 5;83(9):873-886. doi: 10.1016/j.jacc.2023.12.031. J Am Coll Cardiol. 2024. PMID: 38418000
Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model.
Wu R, Williams C, Zhou J, Schlackow I, Emberson J, Reith C, Keech A, Robson J, Armitage J, Gray A, Simes J, Baigent C, Mihaylova B; CTT Collaboration secretariat; Armitage J, Baigent C, Barnes E, Blackwell L, Collins R, Davies K, Emberson J, Fulcher J, Halls H, Herrington WG, Holland L, Keech A, Kirby A, Mihaylova B, O'Connell R, Preiss D, Reith C, Simes J, Wilson K; CTT Collaboration trialists: A to Z trial (phase Z); Blazing M, Braunwald E, Lemos J, Murphy S, Pedersen TR, Pfeffer M, White H, Wiviott S; AFCAPS/TEXCAPS (AirForce/Texas Coronary Atherosclerosis Prevention Study); Clearfield M, Downs JR, Gotto A Jr, Weis S; ALERT (Assessment of Lescol in Renal Transplantation); Fellström B, Holdaas H, Jardine A, Pedersen TR; ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial); Gordon D, Davis B, Furberg C, Grimm R, Pressel S, Probstfield JL, Rahman M, Simpson L; ALLIANCE (Aggressive Lipid-Lowering Initiation Abates New Cardiac Events); Koren M; ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial); Dahlöf B, Gupta A, Poulter N, Sever P, Wedel H; ASPEN (Atorvastatin Study for the Prevention of Coronary Heart Disease Endpoints in Non-Insulin Dependent Diabe… See abstract for full author list ➔ Wu R, et al. Among authors: cannon cp. Br J Gen Pract. 2024 Feb 19;74(740):e189-98. doi: 10.3399/BJGP.2023.0198. Online ahead of print. Br J Gen Pract. 2024. PMID: 38373851 Free PMC article.
Methods, rationale, and design for a remote pharmacist and navigator-driven disease management program to improve guideline-directed medical therapy in patients with type 2 diabetes at elevated cardiovascular and/or kidney risk.
Blood AJ, Chang LS, Colling C, Stern G, Gabovitch D, Feldman G, Adan A, Waterman F, Durden E, Hamersky C, Noone J, Aronson SJ, Liberatore P, Gaziano TA, Matta LS, Plutzky J, Cannon CP, Wexler DJ, Scirica BM. Blood AJ, et al. Among authors: cannon cp. Prim Care Diabetes. 2024 Apr;18(2):202-209. doi: 10.1016/j.pcd.2024.01.005. Epub 2024 Feb 1. Prim Care Diabetes. 2024. PMID: 38302335 Free article. Clinical Trial.
Ticagrelor-Induced Dyspnea: A Controllable Side Effect.
Kim G, Cannon CP. Kim G, et al. Among authors: cannon cp. JACC Cardiovasc Interv. 2023 Oct 23;16(20):2525-2527. doi: 10.1016/j.jcin.2023.09.009. JACC Cardiovasc Interv. 2023. PMID: 37879804 No abstract available.
1,011 results